Management of Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Recommendations of a Multidisciplinary Panel of Experts from South America by Ray Manneh, Ricardo Brugés, Jose Jaime Correa, Julián Rojas, Daniel Rojas, Nicolás Villareal

Get full text

Disease burden and treatment choice for metastatic hormone-sensitive prostate cancer in Colombia by Ray Manneh-Kopp, Marino Cabrera-Fierro, Linda Ibatá, Susan Martínez, Sandra L. Amaya

Get full text

PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis by Ray Manneh, Javier Molina-Cerrillo, Guillermo de Velasco, Linda Ibatá, Susan Martínez, Álvaro Ruiz-Granados, Teresa Alonso-Gordoa

Get full text

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach by Almudena Zapatero, Teresa Alonso-Gordoa, Alfredo Rodríguez Antolín, Felipe Couñago, Felipe Couñago, Noelia Sanmamed, Mario Domínguez Esteban, Marta López Valcárcel, Ray Manneh, Ángel Borque-Fernando, Nuria Sala González, Pablo Maroto

Get full text

Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Ove... by Rodolfo Borges dos Reis MD, PHD, José L. Aguilar-Ponce MD, Federico Cayol MD, MSc, Angela M. Jansen PhD, MHS, Ray Manneh K MD, MSc, Tomas R Merino MD, Gayatri Sanku PhD, MPH, Laura B. Vaca MD, Pedro Isaacsson Velho MD, Ernesto P. Korbenfeld MD

Get full text

Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study by Camillo Porta, Francesco Massari, Tarek Taha, Enrique Grande, Maria T. Bourlon, Ravindran Kanesvaran, Umberto Basso, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Zin W. Myint, Giuseppe Fornarini, Thomas Buttner, Se Hoon Park, Yüksel Ürün, Ugo De Giorgi, Renate Pichler, Pasquale Rescigno, Tomas Buchler, Hana Studentova, Bohuslav Melichar, Jawaher Ansari, Veronica Mollica, Jakub Kucharz, Mimma Rizzo, Alessandro Rizzo, Ray Manneh Kopp, Sebastiano Buti, Fernando Sabino Marques Monteiro, Andrey Soares, Aristotelis Bamias, Matteo Santoni

Get full text

Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1) by Matteo Santoni, Giandomenico Roviello, Enrique Grande, Ugo De Giorgi, Ondrej Fiala, Emmanuel Seront, Javier Molina-Cerrillo, Renate Pichler, Zin W. Myint, Jakub Kucharz, Ravindran Kanesvaran, Thomas Büttner, Martin Pichler, Umberto Basso, Jindrich Kopecky, Maria T. Bourlon, Linda Cerbone, Tomas Buchler, Alvaro Pinto, Alfonso Gómez de Liaño, Caterina Gianni, Anca Zgura, Pasquale Rescigno, Jawaher Ansari, Orazio Caffo, Zsófia Küronya, Maria Giuseppa Vitale, Dipen Bhuva, Martina Catalano, Nuno Vau, Ray Manneh Kopp, Sebastiano Buti, Aristotelis Bamias, Camillo Porta, Kaisa Sunela, Francesco Massari

Get full text

Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study by Maria T. Bourlon, Maria T. Bourlon, Luca Galli, Enrique Grande, Se Hoon Park, Bohuslav Melichar, Timothy J. Schieber, Maria José Juan-Fita, Yüksel Ürün, Javier Molina-Cerrillo, Teresa Alonso-Gordoa, Ugo De Giorgi, Jakub Kucharz, Esther Pérez Calabuig, Vincenza Conteduca, Tarek Taha, Tarek Taha, Pasquale Rescigno, Hussam Abu-Sini, Gian Paolo Spinelli, Ray Manneh Kopp, Alessia Salfi, Dipen Bhuva, Paola Valdez-Sandoval, Sofia Mendez-Bribiesca, Ondrej Fiala, Ondrej Fiala, Sebastiano Buti, Sebastiano Buti, Fernando Sabino Marques Monteiro, Fernando Sabino Marques Monteiro, Aristotelis Bamias, Marwan Ghosn, Francesco Massari, Francesco Massari, Jawaher Ansari, Matteo Santoni

Get full text